ArticleSleep & breathing = Schlaf & Atmung2025
Real-world status of continuous positive airway pressure (CPAP) persistence in patients with sleep apnea syndrome (SAS): a retrospective longitudinal study of administrative claims data in Japan.
Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Baseline Prediction Model for First-Year CPAP Treatment Disengagement in Adults with Obstructive Sleep Apnea: A Secondary Analysis of a Danish Cohort.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo investigate the real-world status of continuous positive airway pressure (CPAP) persistence in patients with sleep apnea syndrome (SAS) using administrative claims data in Japan.
methodsWe designed a retrospective longitudinal study using administrative claims and medical check-up data collected from April 2014 to February 2022. We identified patients newly starting CPAP therapy as their first-line SAS treatment, and assessed patient characteristics, CPAP persistence rates, predictors of CPAP discontinuation, and second-line therapy options.
resultsThe analysis population (n = 13,007) was 76.2% male, and the mean age (± standard deviation) was 64.0 ± 15.0 years. CPAP persistence rates were 90.1% at 90 days, 77.1% at one year, 70.3% at two years, and 66.5% at three years. More discontinuation was noted in patients aged 18 to 44 (adjusted hazard ratio [95% confidence interval]: 1.27 [1.13-1.42]) and ≥ 65 (65-74 years, 1.18 [1.07-1.30]; ≥75 years, 1.59 [1.43-1.76]) than in those aged 45 to 64. Comorbidities of dementia (1.47 [1.25-1.73]), insomnia (1.26 [1.16-1.36]), and restless legs syndrome (RLS, 1.60 [1.16-2.23]) were also associated with more discontinuation. Testing with a Type 3 portable monitor (1.31 [1.21-1.42]), or no record of sleep testing before therapy (1.21 [1.09-1.36]), tended to be associated with more discontinuation than polysomnography. CPAP therapy starting in 2020 (0.72 [0.63-0.82]) and 2021 (0.63 [0.46-0.85]) resulted in better persistence than that starting in 2016. Only 6.1% of patients received second-line therapy after CPAP discontinuation.
conclusionsCPAP therapy was continued for at least a year by about 80% of patients. Because second-line therapies are rarely implemented, efforts are needed to ensure CPAP persistence by considering the factors that influence it. It is also crucial to raise awareness of alternative therapies. REGISTRATION NUMBER: NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.